Virus inactivating agent composition, method for enhancing virus inactivating efficacy, and virus inactivation method

Abstract

To provide a virus inactivating agent composition which exhibits superior rapid effectiveness in virus inactivation, a virus inactivating efficacy enhancement method, and a virus inactivation method.SOLUTION: A virus inactivating agent composition comprises, as (a) a virus inactivating component, one or more selected from the group consisting of 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane salt and chlorhexidine salt in an amount of 0.01 mass% to 5.0 mass%, (b) as a virus inactivating efficacy enhancing component, one or more selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid in an amount of 0.02 mass% to 10.0 mass%, and water, the virus inactivating agent composition having a pH of 1 to 6.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a virus inactivating composition that exhibits excellent rapid-acting efficacy in virus inactivation, a method for enhancing virus inactivation efficacy, and a virus inactivation method. [Background technology]

[0002] Starting with the frequent occurrence of food poisoning cases caused by Escherichia coli O-157, followed by the rampant outbreak of SARS, a new type of pneumonia, food poisoning caused by norovirus has been occurring frequently in recent years. A new strain of influenza broke out in the spring of 2009, bringing the situation to the brink of a pandemic, and interest in disinfection and hygiene has only increased. Since 1996, when there were frequent food poisoning cases caused by Escherichia coli O-157, many household products have been endowed with antibacterial properties, and many of the agents used utilize metal compounds such as silver and copper. For example, antibacterial fibers containing salts of silver bromine or iodine complexes are known (Patent Document 1), but their antifungal effect is weak and their effectiveness against viruses is insufficient.

[0003] Meanwhile, several antiviral agents or products claiming to have antiviral effects have also been proposed. For example, known examples include fibers coated with or mixed with an antiviral agent containing, as an active ingredient, a water-insoluble aromatic hydroxy compound having a phenolic hydroxyl group at at least one site (Patent Document 2), an antiviral finishing agent for fibers containing polyoxyethylene(dimethylimino)ethylene(dimethylimino)ethylene dichloride (Patent Document 3), and antiviral fibers treated with an antiviral agent containing 2-pyridinethiol zinc-1-oxide, 2-pyridinethiol copper-1-oxide, or both of these (Patent Document 4).

[0004] Furthermore, the present applicant focused on 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide and found that this compound is also specifically effective against norovirus (Patent Document 5). Although the norovirus inactivator in Patent Document 5 is excellent, there remains room for further investigation to improve its rapid effectiveness in virus inactivation.

[0005] In particular, in recent years, with the spread of infectious diseases such as the novel coronavirus, opportunities for daily disinfection have increased. Therefore, improving the rapid effectiveness of virus inactivation is an important issue, as it will also lead to a reduction in the time users spend on disinfection. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Laid-Open No. 2008-338481 [Patent Document 2] Japanese Patent Application Laid-Open No. 2005-112748 [Patent Document 3] Japanese Patent Application Laid-Open No. 2008-115506 [Patent Document 4] Japanese Patent Application Laid-Open No. 2009-7736 [Patent Document 5] Patent No. 5377098 Summary of the Invention [Problem to be solved by the invention]

[0007] An object of the present invention is to provide a virus inactivating composition that is excellent in rapid virus inactivation efficacy, a method for enhancing virus inactivation efficacy, and a virus inactivation method. [Means for solving the problem]

[0008] In order to achieve the above object, the present invention provides a virus inactivator composition comprising: (a) 0.01% by mass to 5.0% by mass of one or more virus inactivating components selected from the group consisting of dialkyldimethylammonium salts (wherein the alkyl groups may be the same or different and represent a straight-chain saturated hydrocarbon having 8 to 20 carbon atoms), 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane salts, benzalkonium salts, benzethonium salts, and chlorhexidine salts; and (b) 0.02% by mass to 10.0% by mass of one or more virus inactivation efficacy enhancing components selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid; and water, and having a pH of 1 to 6.

[0009] The present invention also provides a virus inactivator composition characterized by comprising: (a) as a virus inactivating component, 0.01% by mass to 5.0% by mass of one or more selected from the group consisting of dialkyldimethylammonium salts (wherein the alkyl groups may be the same or different and represent a straight-chain saturated hydrocarbon having 8 to 20 carbon atoms), 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane salts, benzalkonium salts, benzethonium salts, and chlorhexidine salts; and (b) as a virus inactivation efficacy enhancing component, 0.02% by mass to 10.0% by mass of fumaric acid and water, and having a pH of 1 to 6.

[0010] The present invention also provides a composition comprising: (a) 0.01% by mass to 5.0% by mass of one or more selected from the group consisting of dialkyldimethylammonium salts (wherein the alkyl groups may be the same or different and represent a straight-chain saturated hydrocarbon having 8 to 20 carbon atoms), 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane salts, benzalkonium salts, benzethonium salts, and chlorhexidine salts as a virus inactivation component; and (b) 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, or the like as a virus inactivation efficacy enhancing component. a virus inactivator composition containing one or more selected from the group consisting of dialkyldimethylammonium salts, benzalkonium salts, and benzethonium salts as a virus inactivation component, and (b) one or more selected from the group consisting of phosphoric acid, lactic acid, and citric acid as a virus inactivation efficacy enhancing component, ethanol, and water, and having a pH of 1 to 6 (however, this does not include hand sanitizers containing a combination of (a) one or more selected from the group consisting of dialkyldimethylammonium salts, benzalkonium salts, and benzethonium salts as a virus inactivation component, and (b) one or more selected from the group consisting of phosphoric acid, lactic acid, and citric acid as a virus inactivation efficacy enhancing component, ethanol, and water). [Effects of the Invention]

[0011] According to the first to third aspects of the present invention, by blending (a) as a virus inactivating component, 0.01% by mass to 5.0% by mass of one or more selected from the group consisting of dialkyldimethylammonium salts (wherein the alkyl groups are the same or different and represent a straight-chain saturated hydrocarbon having 8 to 20 carbon atoms), 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane salts, benzalkonium salts, benzethonium salts, and chlorhexidine salts, and (b) as a virus inactivation efficacy enhancing component, 0.02% by mass to 10.0% by mass of one or more selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid, and water, and adjusting the pH to 1 to 6, a virus inactivator composition can be obtained that is free from alkali irritation to the skin, has an excellent feel when used, and is highly effective in inactivating viruses. DETAILED DESCRIPTION OF THE INVENTION

[0012] The virus inactivating composition of the present invention will be described in detail below. However, the present invention is not intended to be limited to the configurations described in the following embodiments and examples.

[0013] The virus inactivator composition of the present invention is a blend of (a) 0.01% by mass to 5.0% by mass of a cationic virus inactivating component as a virus inactivating component, and (b) 0.02% by mass to 10.0% by mass of one or more components selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid as a virus inactivation efficacy enhancing component, and water.

[0014] It has been known that the (a) cationic virus inactivating component incorporated as a virus inactivating component in the virus inactivator composition of the present invention has a high virus inactivation effect, but there has been room for further study regarding its rapid effectiveness in virus inactivation. The present inventors have now discovered for the first time that the rapid effectiveness in virus inactivation can be synergistically improved by combining the (a) cationic virus inactivating component with one or more acids selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid.

[0015] In the virus inactivator composition of the present invention, in order to sufficiently improve the rapid effect in virus inactivation, (a) the cationic virus inactivating component is blended as the virus inactivating component in an amount of 0.01% by mass to 5.0% by mass to the total amount of the virus inactivating composition, preferably 0.05% by mass to 3.0% by mass, and more preferably 0.10% by mass to 1.0% by mass.

[0016] Examples of cationic virus inactivating components that are blended as (a) virus inactivating component in the virus inactivator composition of the present invention include quaternary ammonium salts, etc. Counter anions of quaternary ammonium salts are not particularly limited, but include fluoride ion (fluoride), chloride ion (chloride), bromide ion (bromide), iodide ion (iodide), methyl sulfate ion (methosulfate), carbonate ion (carbonate), bicarbonate ion (bicarbonate), acetate ion (acetate), propionate ion (propionate), gluconate ion (gluconate), etc. Specific examples of quaternary ammonium salts include 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane salts such as 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dibromide, 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dichloride, and 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dimethosulfate; benzalkonium salts such as benzalkonium chloride and benzalkonium methosulfate; benzethonium salts such as benzethonium chloride and benzethonium methosulfate; cetylpyridinium chloride and cetylpyridinium methosulfate. didecyldimethylammonium salts such as didecyldimethylammonium chloride and decyldimethylammonium methosulfate; dilauryldimethylammonium salts such as dilauryldimethylammonium chloride and dilauryldimethylammonium methosulfate; distearyldimethylammonium salts such as distearyldimethylammonium chloride and distearyldimethylammonium methosulfate; and dioctyldimethylammonium salts such as dioctyldimethylammonium chloride (wherein the alkyl groups may be the same or different and represent a linear saturated hydrocarbon having 8 to 20 carbon atoms).), N,N-didecyl-N-methylpoly(oxyethylene)ammonium salts such as N,N-didecyl-N-methylpoly(oxyethylene)ammonium propionate, N,N-didecyl-N,N-dimethylammonium carbonate / bicarbonate, N,N-didecyl-N,N-dimethylammonium chloride, chlorhexidine salts such as chlorhexidine gluconate and chlorhexidine hydrochloride, octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, dodecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, dodecyldiisopropyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride trialkyl(3-triethoxysilylpropyl)ammonium salts such as ammonium chloride, pentadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, octadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, and octadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride (wherein the alkyl groups are the same or different and represent straight-chain saturated hydrocarbons having 1 to 18 carbon atoms). These cationic virus inactivating components may be used alone or in combination of two or more.

[0017] Among the above cationic virus inactivating components, from the viewpoint of improving the rapid effect in virus inactivation, it is preferable to use 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine gluconate, and octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, and it is more preferable to use 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide.

[0018] The organic acid and / or inorganic acid to be incorporated into the virus inactivator composition of the present invention as (b) a virus inactivation efficacy enhancing component may be one or more selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid, with one or more selected from the group consisting of fumaric acid, phosphoric acid, and lactic acid being preferred, and fumaric acid and / or phosphoric acid being preferred. By using these organic acids and / or inorganic acids, the rapid-acting effect of virus inactivation can be more significantly improved even when the cationic virus inactivating component, which is the virus inactivating component, is incorporated in a low amount. These organic acids and / or inorganic acids may be used alone or in combination of two or more.

[0019] The pH of the virus inactivator composition of the present invention is preferably 1 to 6. This makes the virus inactivator composition acidic to weakly acidic, and the virus inactivator composition is less corrosive to the skin than alkaline virus inactivators, resulting in a virus inactivator composition with excellent usability.

[0020] The amount of (b) the virus inactivation efficacy enhancing component in the virus inactivator composition of the present invention is not particularly limited. However, if the amount is too small, the effect of sufficiently improving the rapid effectiveness of the cationic virus inactivating component in virus inactivation may not be obtained.

[0021] As will be shown in the Examples below, in order to sufficiently improve the rapid effectiveness of virus inactivation, (b) the organic acid and / or inorganic acid serving as the virus inactivation efficacy enhancing component is blended in an amount of 0.02% by mass or more and 10.0% by mass or less, preferably 0.03% by mass or more and 5.0% by mass or less, and more preferably 0.10% by mass or more and 2.0% by mass or less, relative to the virus inactivator composition.

[0022] In the virus inactivator composition of the present invention, the blending mass ratio (a) / (b) of (a) the virus inactivating component and (b) the virus inactivation efficacy enhancing component is 0.001≦(a) / (b)≦250, preferably 0.005≦(a) / (b)≦100, and more preferably 0.01≦(a) / (b)≦50, thereby providing a virus inactivator composition that can further improve the rapid effectiveness in virus inactivation.

[0023] The virus inactivator composition of the present invention preferably further contains 10% to 80% by mass of (c) ethanol. By containing 10% to 80% by mass of (c) ethanol, the rapid-acting effect in virus inactivation can be improved. Furthermore, the volatility of the virus inactivator composition is improved, resulting in a virus inactivator composition with excellent quick-drying properties. Of these, the content of (c) ethanol is more preferably 35% to 65% by mass, and even more preferably 55% to 65% by mass of (c) ethanol. By using these amounts, the rapid-acting effect in virus inactivation can be more effectively improved, skin irritation is less likely to occur during use, and the volatility of the virus inactivator composition is effectively improved, resulting in a virus inactivator composition with excellent quick-drying properties.

[0024] The virus inactivator composition of the present invention can be blended with a surfactant as needed. For example, surfactants have the property of generating foam (foaming ability), and so using a surfactant with excellent foaming ability has the advantage of suppressing dripping when the virus inactivator composition of the present invention is sprayed onto a wall surface with a trigger spray or the like, and also making it easier to visually confirm the applied area.

[0025] As the surfactant to be incorporated into the virus inactivator composition of the present invention, any of anionic surfactants, nonionic surfactants, and amphoteric surfactants can be suitably used. The amount of surfactant incorporated into the virus inactivator composition of the present invention is not particularly limited, but is preferably 0.1% by mass or more and 10% by mass or less. Note that cationic virus inactivating components incorporated into the virus inactivator composition of the present invention are not included in the surfactants in this specification.

[0026] Examples of anionic surfactants include fatty acid soaps, alkylbenzene sulfonates, linear alkylbenzene sulfonates, alkyl sulfates, α-olefin sulfonates, alkyl phosphates, polyoxyethylene alkyl ether sulfates, polyoxyethylene alkyl phenyl ether sulfates, and polyoxyethylene alkyl ether phosphates.

[0027] Examples of nonionic surfactants include polyoxyethylene alkyl ethers, polyoxyethylene alkylphenyl ethers, polyoxyethylene higher fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyoxyethylene hydrogenated castor oil, coconut oil fatty acid diethanolamide, polyoxyethylene polyoxypropylene alkyl ethers, fatty acid alkanolamides, and alkylamine oxides.

[0028] Examples of amphoteric surfactants include betaine surfactants, such as lauryl-N,N-dimethylacetate betaine, laurylamidopropyl-N,N-dimethylacetate betaine, and coconut alkylamidopropyl-N,N-dimethylhydroxypropyl sulfobetaine.

[0029] The virus inactivating composition of the present invention is an aqueous type, and water is used mainly as a solvent. Examples of water include purified water such as ion-exchanged water and reverse osmosis water, ordinary tap water, industrial water, and deep sea water.

[0030] Furthermore, the virus inactivator composition of the present invention may contain other components, such as antibacterial agents, virus inactivators, antialgae agents, antirust agents, solvents, chelating agents, fragrances, deodorizing components, pH adjusters, moisturizing components, and thickeners, as needed, other than cationic virus inactivating components, within a range that does not impair the effects of the present invention, thereby imparting antibacterial effects, virus inactivating effects, antialgae effects, antirust effects, cleaning effects, fragrances, deodorizing properties, moisturizing effects, thickening effects, and the like.

[0031] Examples of other antibacterial and viral inactivating agents include isopropylmethylphenol (IPMP), carvacrol, thymol, triclosan, methylparaben, ethylparaben, propylparaben, butylparaben, 4-chloro-3,5-dimethylphenol, orthophenylphenol, o-cresol, m-cresol, p-cresol, tebuconazole, enilconazole, grapefruit seed extract, persimmon seed extract, grape seed extract, monolaurin, monocaprin, monocaprylin, benzoic acid, sorbic acid, glycine, alkyldiethylaminoglycine, polylysine, dehydroacetic acid, sodium dehydroacetate, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, silver zeolite, zinc pyrithione, thiamine lauryl sulfate, milt protein, hydroxyalkylchitosan, and chitosan.

[0032] Examples of anti-algae agents include sodium dichloroisocyanurate, etc. Examples of rust inhibitors include sodium benzoate, etc.

[0033] Examples of the solvent include hydrocarbon solvents such as normal paraffin, isoparaffin, liquid paraffin, naphthenic hydrocarbons, petrolatum, squalane, and α-olefin oligomers; alcohol solvents such as 1-propanol, 2-propanol (IPA), 1-butanol, 2-butanol, tertiary butanol, 1-pentanol, 1-hexanol, benzyl alcohol, and 2-phenylethanol; and glycol solvents such as 2-phenoxyethanol (ethylene glycol monophenyl ether), ethylene glycol, propylene glycol, 1-phenoxy-2-propanol (propylene glycol phenyl ether), 1,3-butylene glycol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, and tripropylene glycol monobutyl ether.

[0034] Examples of fragrances include hydrocarbon fragrances such as limonene such as d-limonene, pinene such as α-pinene and β-pinene, cymene such as p-cymene, indene, and caryophyllene, menthol such as linalool, geraniol, citronellol, and l-menthol, ethyl linalool, borneol, anise alcohol, β-phenethyl alcohol, p-menthane-3,8-diol, terpineol such as α-terpineol and γ-terpineol, 1-hexenol, cis-3-hexen-1-ol, tetrahydrogeraniol, santalinol, cinnamyl alcohol, and sesame oil. Alcohol-based fragrances such as dolor, ether-based fragrances such as galaxolide, β-naphthyl methyl ether, cineole, ambroxide, p-cresyl methyl ether, phenol-based fragrances such as anethole, eugenol, isoeugenol, vanillin, ethyl vanillin, octanal, nonanal, undecyl aldehyde, undecanal, decyl aldehyde, n-butyraldehyde, isobutyraldehyde, hexyl aldehyde, citral, citronellal, benzaldehyde, cinnamic aldehyde, anisaldehyde, cumin aldehyde, adoxar Aldehyde fragrances such as ethanol, amyl cinnamic aldehyde, and cyclamen aldehyde; ketone fragrances such as musk ketone, carvone, menthone, camphor, camphor, acetophenone, butyrophenone, tonalide, α-ionone, β-ionone, α-methyl ionone, β-methyl ionone, α-isomethyl ionone, β-isomethyl ionone, γ-methyl ionone, γ-isomethyl ionone, damascone, α-damascone, β-damascone, acetyl cedrene, cashmeran, cis-jasmone, and dihydrojasmone; γ-butyrolactone, γ-nonalactone, γ Lactone fragrances such as decalactone, γ-undecalactone, coumarin, cineole, ambrette, and jasmolactone, geranyl formate, octyl acetate, geranyl acetate, benzyl acetate, cinnamyl acetate, tetrahydrogeranyl acetate, menthyl acetate, linalyl acetate, butyl propionate, benzyl acetate, methyl benzoate, allyl hexanoate, allyl heptanoate, allyl cyclohexane propionate, allyl amyl glycolate, amyl valerianate, amyl salicylate, isoamyl acetate,Ester-based fragrances such as butyl acetate, ethyl butyrate, acetyleugenol, isoamyl salicylate, allyl caproate, ethyl caproate, ethyl propionate, ethyl acetoacetate, methyl salicylate, citronellyl acetate, citronellyl formate, cinnamyl acetate, stearyl acetate, stearyl propionate, cedryl acetate, terpinyl acetate, amyl cinnamic aldehyde dimethyl acetate Acetal fragrances such as citral dimethyl acetal, indole, geranyl nitrile, citronellyl nitrile, acetaldehyde phenylethyl propyl acetate, thesalon, auranthiol, linalool oxide, mint oil, orange oil, lemon oil, lavender oil, peppermint oil, eucalyptus oil, citronella oil, lime oil, yuzu oil, jasmine oil, cypress oil, green tea essential oil, neroli oil, geranium oil, petitgrain oil, lemongrass oil, cinnamon oil, lemon Eucalyptus oil, thyme oil, perilla oil, pine oil, rose oil, rosemary oil, camphor oil, aromatic oil, clary sage oil, sandalwood oil, spearmint oil, star anise oil, lavandin oil, oakmoss oil, ocotia oil, patchouli oil, tonka bean tincture, turpentine oil, wanilla bean tincture, basil oil, nutmeg oil, clove oil, bois de rose oil, cananga oil, cardamom oil, cassia oil, cedarwood oil, mandarin oil, tangerine oil, anise oil, bay oil, coriander Examples of oils that can be used include laurel oil, elemi oil, fennel oil, galbanum oil, cypress oil, vetiver oil, bergamot oil, ylang-ylang oil, grapefruit oil, abies oil, accion oil, almond oil, angelica root oil, peper oil, mint oil, perch oil, bois rose oil, kayabuchi oil, gananga oil, capsicum oil, caraway oil, celery oil, cognac oil, cumin oil, jill oil, estgolan oil, garlic oil, ginger oil, hop oil, sage oil, and turpentine oil.

[0035] Examples of deodorizing ingredients include sugarcane extract, green tea extract, dry tea distillate, persimmon extract, grapefruit extract, mozo bamboo extract, yuzu seed extract, and forsythia extract. Sugarcane extract is preferred from the viewpoint of promoting norovirus inactivation in addition to its deodorizing effect.

[0036] Examples of pH adjusters include other organic acids such as acetic acid, malic acid, salicylic acid, other inorganic acids such as hydrochloric acid, sodium citrate, sodium carbonate, sodium bicarbonate, sodium hydroxide, and the like.

[0037] Examples of moisturizing ingredients include glycols such as glycerin, propylene glycol, and 1,3-butylene glycol, and polyhydric alcohols such as sorbitol.

[0038] Examples of thickeners include carboxyvinyl polymers, which are cross-linked polyacrylic acids; cellulose derivatives such as carboxymethyl cellulose, hydroxyethyl cellulose, and hydroxypropyl cellulose; xanthan gum, guar gum, gum arabic, sodium alginate, propylene glycol alginate, ethyl cellulose, sodium polyacrylate, and cyclodextrin.

[0039] The virus inactivator composition of the present invention thus obtained can be applied or sprayed onto virus-contaminated areas such as areas touched by a virus-infected person, areas where vomit from a virus-infected person has been disposed of, and clothing, to effectively remove viruses.

[0040] Furthermore, by applying or spraying the virus inactivating composition of the present invention to hands, etc., viruses adhering to hands, etc. can be effectively removed, and hands, etc. can be disinfected.

[0041] Furthermore, the virus inactivating composition of the present invention has a high inactivation effect not only on enveloped viruses such as influenza virus, coronavirus, and herpes virus, but also on non-enveloped viruses such as norovirus, rotavirus, rhinovirus, and adenovirus, and can therefore be suitably used to inactivate norovirus, which has been difficult to inactivate with conventional virus removal agents.

[0042] Furthermore, the virus inactivator composition of the present invention has a very simple composition, being composed simply by blending a cationic virus inactivating component as the virus inactivating component and a specific organic acid and / or inorganic acid as the virus inactivation efficacy enhancing component into water. Therefore, production is easy. Furthermore, since there is no problem of discoloration due to silver ions, it is also easy to use.

[0043] It should be noted that the present invention is not limited to the above-described embodiments, and various modifications are possible within the scope of the claims, and embodiments obtained by appropriately combining the technical means disclosed in different embodiments are also included in the technical scope of the present invention. The effects of the present invention will be explained in more detail below using examples, but the present invention is not limited to these examples. [Example]

[0044] [Preparation of test solution] (a) 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide (Hygenia S-100, manufactured by Tama Chemical Industry Co., Ltd.), benzalkonium chloride (Cation F2-50R, manufactured by NOF Corporation), benzethonium chloride (manufactured by Fujifilm Wako Pure Chemical Industries Co., Ltd.), didecyldimethylammonium chloride (Lipoguard 210-80E, manufactured by Lion Specialty Chemicals Co., Ltd.), 20% chlorhexidine gluconate aqueous solution (manufactured by Fujifilm Wako Pure Chemical Industries Co., Ltd.), (b) fumaric acid, phosphoric acid, lactic acid, citric acid monohydrate (all manufactured by Fujifilm Wako Pure Chemical Industries Co., Ltd.), and (c) ethanol were blended in the blending ratios (mass%) shown in Tables 1 and 3, and purified water was added to make up 100 mass% to obtain test solutions (present inventions 1 to 21).

[0045] (a) 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide (Hygenia S-100, manufactured by Tama Chemical Industry Co., Ltd.), benzalkonium chloride (Cation F2-50R, manufactured by NOF Corporation), benzethonium chloride (manufactured by Fujifilm Wako Pure Chemical Industries Co., Ltd.), didecyldimethylammonium chloride (Lipoguard 210-80E, manufactured by Lion Specialty Chemicals Co., Ltd.), isopropylmethylphenol (manufactured by Fujifilm Wako Pure Chemical Industries Co., Ltd.), (b) fumaric acid, phosphoric acid, and lactic acid (all manufactured by Fujifilm Wako Pure Chemical Industries Co., Ltd.), and (c) ethanol were blended in the blending ratios (mass%) shown in Tables 2 and 4, and purified water was added to make the total 100 mass%, to obtain test solutions (Comparative Examples 1 to 15). [Example]

[0046] [Confirmation test for virus inactivation effect 1 (Feline calicivirus)] (Preparation of test virus solution) CRFK cells (JCRB Cell Bank) were cultured in monolayers in tissue culture dishes using a cell growth medium consisting of MEM medium (Nacalai Tesque, Inc.) supplemented with 10% fetal bovine serum. The cell growth medium was removed from the monolayer culture dish, and feline calicivirus (Feline calicivirus F-9 ATCC VR-782) was inoculated. Next, a cell maintenance medium consisting of MEM medium supplemented with 2% fetal bovine serum was added, and the cells were cultured in a carbon dioxide incubator (5% CO2 concentration) at 37 ± 1°C for 1 to 5 days. Feline calicivirus is a non-enveloped virus and is widely used as an alternative to norovirus, which cannot be cultured in cells.

[0047] After incubation, the cell morphology was observed using an inverted phase-contrast microscope to confirm the occurrence of morphological changes (cytopathic effect) in the cells. The culture medium was then centrifuged at 1000 rpm for 3 minutes, and the resulting supernatant was ultrafiltered to obtain the test virus solution.

[0048] 0.1 mL of the test virus solution was added to 0.9 mL of the test solutions of Inventions 1 to 10 and Comparative Examples 1 to 6 prepared in Example 1 and mixed to prepare working solutions. After 1 minute, the working solutions were diluted 100-fold with MEM medium to prepare a 10-fold dilution series. Note that the same procedure was carried out using phosphate-buffered saline to which the test virus solution was added as a control.

[0049] (Measurement of virus infectivity) The cells used were cultured in monolayers in tissue culture microplates (96 wells) using cell growth medium, and then the cell growth medium was removed and 0.1 mL of cell maintenance medium was added to each well. Next, 0.1 mL of a 10-fold serial dilution of the working solution was inoculated into four wells each and cultured for 4 to 7 days in a carbon dioxide incubator (CO2 concentration 5%) at 37 ± 1°C. After culturing, the presence or absence of cell morphological changes (cytopathic effect) was observed using an inverted phase contrast microscope, and the 50% cell culture infectious dose (TCID) was determined using the Reed-Muench method. 50 ) was calculated and converted into the infectivity titer per mL of the action solution, and the infectivity titer was compared with the infectivity titer of purified water used as a control to calculate the log reduction in the infectivity titer.

[0050] The evaluation criteria for virus removal effect were as follows: × if the log reduction in infectivity value was less than 1, △ if it was 1 or more but less than 1.5, ○ if it was 1.5 or more but less than 2, and ◎ if it was 2 or more. The evaluation results of virus infectivity value are shown in Tables 1 and 2, along with the formulation of the test solution and the log reduction in infectivity value.

[0051] [Table 1]

[0052] [Table 2]

[0053] As shown in Table 1, Inventions 1 to 10, which contain (a) 0.01% by mass to 5.0% by mass of any of cationic virus inactivating ingredients, 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, and chlorhexidine gluconate, and (b) 0.02% by mass to 10.0% by mass of any of fumaric acid, phosphoric acid, and lactic acid, exhibited a log reduction in infectivity against feline calicivirus of 1.5 or more, confirming that they have a virus inactivation effect.

[0054] In particular, in Invention 3, in which the blending amount of 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide was 0.10% by mass and the blending amount of fumaric acid was 0.2% by mass, and Invention 5, in which the blending amount of 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide was 0.10% by mass and the blending amount of phosphoric acid was 0.2% by mass, the log reduction in infectivity titer was greater than 3, and it was confirmed that even more excellent virus inactivation effects could be obtained.

[0055] In contrast, as shown in Table 2, in Comparative Examples 5 and 6, which contained only component (a), and in Comparative Examples 1 to 3, which contained only component (b), the log reduction in infectivity against feline calicivirus was less than 1.5, and a sufficient virus inactivation effect was not observed. Furthermore, in Comparative Example 4, in which component (a) was replaced with a cationic virus inactivating component and another virus inactivating component, isopropylmethylphenol, was used, no rapid virus inactivation effect was obtained even when component (b) was used in combination, and no enhancing effect of component (b) was observed. [Example]

[0056] [Confirmation test for virus inactivation effect 2 (Feline calicivirus)] (Preparation of test virus solution) CRFK cells (JRBC Cell Bank) were cultured in monolayers in tissue culture dishes using a cell growth medium consisting of MEM medium (Nacalai Tesque) supplemented with 10% fetal bovine serum. The cell growth medium was removed from the monolayer culture dish, and feline calicivirus F-9 (ATCC VR-782) was inoculated. Next, a cell maintenance medium consisting of MEM medium supplemented with 2% fetal bovine serum was added, and the cells were cultured in a carbon dioxide incubator (5% CO2 concentration) at 37±1°C for 1 to 5 days.

[0057] After incubation, the cell morphology was observed using an inverted phase-contrast microscope to confirm the occurrence of morphological changes (cytopathic effect) in the cells. The culture medium was then centrifuged at 1000 rpm for 3 minutes, and the resulting supernatant was ultrafiltered to obtain the test virus solution.

[0058] 0.1 mL of the test virus solution was added to 0.9 mL of the test solutions of Inventions 11 to 21 and Comparative Examples 7 to 15 prepared in Example 1 and mixed to prepare working solutions. After 20 seconds, the working solutions were diluted 100-fold with MEM medium to prepare a 10-fold dilution series. Note that the same procedure was carried out using phosphate-buffered saline to which the test virus solution was added as a control.

[0059] The method for measuring the virus infectivity and the evaluation criteria were the same as in Example 2. The evaluation results of the virus infectivity are shown in Tables 3 and 4 together with the formulation of the test solution and the log reduction in the infectivity.

[0060] [Table 3]

[0061] [Table 4]

[0062] As shown in Table 3, Inventions 11 to 21, which contained (a) 0.01% by mass to 5.0% by mass of any of cationic virus inactivating ingredients, 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, and chlorhexidine gluconate, and (b) 0.02% by mass to 10.0% by mass of any of fumaric acid, phosphoric acid, lactic acid, and citric acid monohydrate, had a log reduction in infectivity against feline calicivirus of 2.5 or more, and showed sufficient virus inactivation effect even 20 seconds after treatment, confirming that they had excellent rapid-acting virus inactivation effect.

[0063] In particular, it was confirmed that Invention 11 and Invention 12, in which the amount of 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide was 0.10% by mass and the amount of fumaric acid was 0.04% by mass and 0.20% by mass, respectively; Invention 13, Invention 14, and Invention 15, in which the amount of 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide was 0.10% by mass and the amount of phosphoric acid was 0.02%, 0.03% by mass, and 0.20% by mass, respectively; and Invention 17, in which the amount of 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane dibromide was 0.10% by mass and the amount of citric acid monohydrate was 0.20% by mass, had an infectivity log reduction of more than 3.0, and a more rapid virus inactivation effect was obtained.

[0064] In contrast, as shown in Table 4, in Comparative Examples 11 to 14, which contained only component (a), and in Comparative Examples 7 to 9, which contained only component (b), the log reduction in infectivity against feline calicivirus was less than 1.5, and a sufficient rapid-acting virus inactivation effect was not observed. Furthermore, in Comparative Example 10, in which component (a) was replaced with a cationic virus inactivating component and another virus inactivating component, isopropylmethylphenol, was used, no rapid-acting virus inactivation effect was obtained even when component (b) was used in combination, and no enhancing effect of component (b) was observed. [Example]

[0065] [Confirmation test for virus inactivation effect 3 (Feline enteric coronavirus)] (Preparation of test virus solution) Feline coronavirus (Feline enteric coronavirus) was infected into feline fetal cells (FCWF-4: feline catus whole fetus), and when approximately 90% or more of the cell culture area showed cytopathic effects, the cells were stored in a refrigerator at -80°C. After that, the cells were subjected to a freeze-thawing procedure, and the supernatant was centrifuged at 3500 rpm for 10 minutes. The virus solution was concentrated using an ultrafiltration membrane and used as the test virus.

[0066] 0.1 mL of the test virus solution was added to 0.9 mL of the test solution of Invention 12 prepared in Example 1 and mixed to prepare a working solution. After 3 minutes, the working solution was diluted 100-fold with MEM medium to stop the action, and this was used as a stock solution for the infectivity titer measurement sample, and the virus infectivity titer was measured. Note that the same procedure was performed as a control, where the test virus solution was added to phosphate-buffered saline.

[0067] As a result of the test, in the infectivity titer measurement sample treated with the virus inactivator composition of present invention 12, feline coronavirus (Feline enteric coronavirus) was below the detection limit after 3 minutes, indicating that the virus inactivator composition of present invention 12 exhibits a virus inactivation effect against feline coronavirus (Feline enteric coronavirus).

[0068] The present invention relates to a virus inactivator composition that exhibits excellent rapid-acting efficacy in virus inactivation, a method for enhancing virus inactivation efficacy, and a virus inactivation method, and is particularly suitable for use as a virus inactivator composition that is directly applied by spraying or the like to a site or the like that is contaminated with a virus.

Claims

1. A virus inactivator composition comprising: (a) 0.01% by mass to 5.0% by mass of one or more virus inactivating components selected from the group consisting of 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane salts and chlorhexidine salts; (b) 0.02% by mass to 10.0% by mass of one or more virus inactivating effect enhancing components selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid; and water; and having a pH of 1 to 6.

2. A virus inactivator composition comprising: (a) as a virus inactivating component, 0.01% by mass to 5.0% by mass of one or more selected from the group consisting of dialkyldimethylammonium salts (wherein the alkyl groups may be the same or different and represent a straight-chain saturated hydrocarbon having 8 to 20 carbon atoms), 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane salts, benzalkonium salts, benzethonium salts, and chlorhexidine salts; and (b) as a virus inactivation efficacy enhancing component, 0.02% by mass to 10.0% by mass of fumaric acid and water, wherein the virus inactivating composition has a pH of 1 to 6.

3. (a) as a virus inactivation component, 0.01% by mass to 5.0% by mass of one or more selected from the group consisting of dialkyldimethylammonium salts (wherein the alkyl groups may be the same or different and represent a straight-chain saturated hydrocarbon having 8 to 20 carbon atoms), 1,4-bis(3,3'-(1-decylpyridinium)methyloxy)butane salts, benzalkonium salts, benzethonium salts, and chlorhexidine salts; and (b) as a virus inactivation efficacy enhancing component, 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, A virus inactivator composition comprising one or more components selected from the group consisting of dialkyldimethylammonium salts, benzalkonium salts, and benzethonium salts as a virus inactivation component, and (b) one or more components selected from the group consisting of phosphoric acid, lactic acid, and citric acid as a virus inactivation efficacy enhancing component, ethanol, and water, and having a pH of 1 to 6 (however, this does not include hand sanitizers comprising a combination of (a) one or more components selected from the group consisting of dialkyldimethylammonium salts, benzalkonium salts, and benzethonium salts as a virus inactivation component, and (b) one or more components selected from the group consisting of phosphoric acid, lactic acid, and citric acid as a virus inactivation efficacy enhancing component, ethanol, and water).

Images